The pharmacologic modulation of the release of arachidonic acid metabolites from purified human lung mast cells.

Although cyclooxygenase and lipoxygenase inhibitors have been widely used in studies of allergic and inflammatory disorders, the effect of these agents has not been determined on mediators released from purified human lung mast cells. The release of histamine, prostaglandin D2, leukotriene C4, leukotriene B isomers, 5-hydroxyeicosatetraenoic acid (5-HETE), and free arachidonic acid (AA) from preparations of purified human lung mast cells (90 +/- 2% pure) prelabeled with 3H-AA as modified by indomethacin, eicosatriynoic acid (ETI), and diethylcarbamazine (DEC) was determined. Indomethacin (3 microM) markedly (greater than 90%) inhibited the anti-IgE- and ionophore A23187-induced release of PGD2 from these cells but had no effect on the release of histamine or other AA metabolites. Specifically, no increase in LTC production was noted, and no large amount of shunting of products into those produced by lipoxygenases was noted. The ETI, a lipoxygenase inhibitor in many systems, inhibited the release of histamine, PGD2, LTC, LTB isomers, 5-HETE, and free AA, all with an IC50 between 3 and 10 microM. The lack of specificity for lipoxygenase products together with a similar potency for inhibition of histamine release suggests that ETI may act at an early event in the activation process of these cells, apparently prior to the action of phospholipase(s), which releases AA from cellular stores. The DEC inhibited PGD2 release in purified mast cells and histamine release in pure and crude preparations of mast cells, both with IC50 values ranging from 1 to 3 mM. No specificity for enzymes responsible for the production of LTA4 was observed in these cells, unlike the results reported in other systems.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  R. Naclerio,et al.  IgE-mediated release of inflammatory mediators from human basophils and mast cells in vitro and in vivo , 1984 .

[2]  H. Dvorak,et al.  Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. , 1983, Journal of immunology.

[3]  R. Egan,et al.  Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. , 1983, Journal of immunology.

[4]  S. Peters,et al.  Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. , 1983, The Journal of clinical investigation.

[5]  S. Peters,et al.  Comparative studies of human basophils and mast cells. , 1983, Federation proceedings.

[6]  R. Robertson,et al.  Lipoxygenase pathway in islet endocrine cells. Oxidative metabolism of arachidonic acid promotes insulin release. , 1983, The Journal of clinical investigation.

[7]  S. Dahlén,et al.  Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Peters,et al.  Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments. , 1982, The American review of respiratory disease.

[9]  F. Fitzpatrick,et al.  Anaphylactic release of thromboxane A2, prostaglandin D2, and prostacyclin from human lung parenchyma. , 1981, The American review of respiratory disease.

[10]  M. A. Bray,et al.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes , 1980, Nature.

[11]  L. Lichtenstein,et al.  Anaphylactic release of prostaglandins from human lung in vitro. , 1980, The American review of respiratory disease.

[12]  J. Adcock,et al.  A POSSIBLE ROLE FOR LIPOXYGENASE PRODUCTS AS REGULATORS OF AIRWAY SMOOTH MUSCLE REACTIVITY , 1980, British journal of pharmacology.

[13]  N. Paterson,et al.  Evidence for lipoxygenase pathway involvement in allergic tracheal contraction. , 1980, Prostaglandins.

[14]  J. Salmon,et al.  The mechanism of enhancement by fatty acid hydroperoxides of anaphylactic mediator release. , 1978, Prostaglandins.

[15]  U. Niederhauser,et al.  RELEASE OF MEDIATORS OF ANAPHYLAXIS: INHIBITION OF PROSTAGLANDIN SYNTHESIS AND THE MODIFICATION OF RELEASE OF SLOW REACTING SUBSTANCE OF ANAPHYLAXIS AND HISTAMINE , 1978, British journal of pharmacology.

[16]  H. Gilbert,et al.  Basophil counting with a new staining method using alcian blue. , 1975, Blood.

[17]  R. Siraganian.  An automated continuous-flow system for the extraction and fluorometric analysis of histamine. , 1974, Analytical biochemistry.

[18]  K. Ishizaka,et al.  Release of histamine and slow reacting substance of anaphylaxis (SRS-A) by IgE-anti-IgE reactions on monkey mast cells. , 1972, Journal of immunology.

[19]  M. Kaliner,et al.  IMMUNOLOGICAL RELEASE OF HISTAMINE AND SLOW REACTING SUBSTANCE OF ANAPHYLAXIS FROM HUMAN LUNG , 1971, The Journal of experimental medicine.

[20]  L. Lichtenstein,et al.  The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. , 1971, Journal of immunology.

[21]  K. Austen,et al.  Pharmacologic inhibition of the antigen-induced release of histamine and slow reacting substance of anaphylaxis (SRS-A) from monkey lung tissues mediated by human IgE. , 1971, Journal of immunology.

[22]  E. Assem,et al.  Inhibition by Sympathomimetic Amines of Histamine Release induced by Antigen in Passively Sensitized Human Lung , 1969, Nature.

[23]  J. Mongar,et al.  Reactions of isolated human asthmatic lung and bronchial tissue to a specific antigen; histamine release and muscular contraction. , 1951, Lancet.